Displaying 172 (all) recruiting clinical trials.
-
A Randomized Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-na ve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
This is a Phase 2 study testing two different medicines to treat a blood cancer called GCB DLBCL(diffuse large B-cell lymhoma). Zilovertamab Vedotin (an ...
Phase
Interventional
-
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy
Despite clear advances that have been taking place in the treatment of advanced RCC in recent years, there are still unmet medical needs and opportunities ...Phase
Interventional
-
A Randomised Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1 BRCA2 or PALB2 Mutations and Hormone Receptor Positive HER2-Negative (IHC 0 1+ 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
This study is testing how well a new medicine, saruparib (AZD5305), works when combined with camizestrant compared to other common treatments for advanced breast cancer ...
Phase
Interventional
-
Expanded Access Treatment of Neladalkib (NVL-655) in Patients with Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
This is a study testing a medicine called Neladalkib (a type of ALK blocker) for patients who have ALK-positive non-small cell lung cancer (NSCLC) that ...
Phase N/A Interventional
-
Global Phase 3 Randomized Open-Label Study to Evaluate Efficacy & Safety of Firmonertinib Comp.w/ Osimertinib or Afatinib as 1st line Treat. in Pts. w/ Locally Advanced or Metastatic NSCLC with EGFR PACC Uncommon Mutations (Alpacca)
This is a Phase 3 study testing the safety and effectiveness of the new medicine firmonertinib (an EGFR-tyrosine kinase inhibitor) and comparing it with standard ...
Phase
Interventional
-
A Phase II Study of DRP-104 a glutamine antagonist in patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer and Gastroesophageal Cancer
This is a Phase 2 study testing a new medicine called DRP-104 (a glutamine antagonist) in patients with non-small cell lung cancer (NSCLC). These patients ...
Phase
Interventional
-
A Phase I Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors
This is a Phase 1 study testing the study medicine GSK5733584 (B7-H4 targeted antibody-drug conjugate (ADC )) in patients with advanced solid tumors. The study drug ...
Phase
Interventional
-
A Phase 1 Open-Label Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid ...Phase
Interventional
-
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
This is a Phase 2 study testing whether a combination of TAS-102 and fruquintinib (a selective oral kinase inhibitor) is more effective and safer than ...
Phase
Interventional
-
A Modular Phase I/II Open-label Multicentre Study to Evaluate the Safety PK PD Immunogenicity and Efficacy of AZD4512 Monotherapy or in Combination with other Anticancer agent(s) in subjects with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I/II study testing whether the new medicine AZD4512 is safe, effective, and well-tolerated in patients with B-cell Non-Hodgkin Lymphoma (B-NHL ...
Phase
Interventional
